Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha

Area of Science:

• Hepatology
• Lipidology
• Pharmacology

Background:

• Chronic hepatitis C is a significant global health concern.
• Interferon-alpha has been a key treatment for chronic hepatitis C.
• Understanding treatment-induced metabolic changes is crucial for patient management.

Purpose of the Study:

• To assess the impact of interferon-alpha therapy on the lipid profiles of patients with chronic hepatitis C.
• To identify specific lipid parameters affected by this treatment.
• To evaluate the safety of interferon-alpha therapy concerning lipid abnormalities.

Main Methods:

• Prospective evaluation of fasting lipoproteins in 36 chronic hepatitis C patients.
• Lipid profiles assessed at baseline, during therapy (1, 3, 6 months), and post-treatment (3 months).
• Analysis included total cholesterol, VLDL, LDL, HDL, triglycerides, apolipoproteins (apo) A1 and B, and lipoprotein (a).

Main Results:

• Interferon-alpha therapy led to increased total and VLDL-triglycerides, VLDL-cholesterol, and apo B.
• A decrease in HDL-cholesterol and apo A1 levels was observed.
• Three patients developed chylomicronemia and severe hypertriglyceridemia, particularly those with baseline triglycerides >200 mg/dl.

Conclusions:

• Interferon-alpha therapy significantly alters lipid profiles in chronic hepatitis C patients.
• Increased triglycerides and VLDL-cholesterol, with decreased HDL-cholesterol, are key changes.
• Monitoring triglyceride levels during therapy is vital to prevent complications like chylomicronemia.